19th Biennial Symposium on Purine and Pyrimidine Metabolism (PP21)
In June 2021 the Purine and Pyrimidine Society organized the biannual meeting online. At this meeting a number of different aspects of nucleoside and nucleotide metabolism were discussed focusing on inborn errors of metabolism (e.g. novel developments on the Lesch-Nyhan syndrome, mitochondrial diseases, gout) and on cancer drug metabolism (how to improve "old" drugs, development of new drugs, new approaches for "old" targets). Next novel developments on regulation of nucleoside transporters and drug efflux pumps (e.g. ABCG2 which plays a role in efflux of uric acid) were discussed and how they play a role in drug metabolism. An important subject was degradation of nucleotides, both of mononucleotides (e.g. the role of CD73), but also molecules such as NUDT22, CD39 and SAMHD1, which play a role in degradation of di-, and trinucleotides and of nucleotide analogs. They may constitute an important form of drug resistance. There was a separate session on purine and pyrimidine metabolism in the microbiome, both from a metabolic point of view, but also regarding their potential role in drug resistance.
Edited by
Lars Petter Jordheim
Godefridus J. Peters
S. Peyrottes